Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be highly variable between patients. To date, the approval of Benlysta in 2011 is the most notable development in the SLE market following the failure of several promising therapies to pass their Phase III programs. However, Benlysta’s modest efficacy is a major deterrent to its uptake. The unmet need remains high for effective SLE therapies, and several pharmaceutical companies are attempting to enter this market with multiple pending molecules. As these new SLE therapies seek to launch, the Disease Landscape and Forecast provides detailed analyses into current medical practice, key unmet needs, and new developments in the SLE space, along with an analysis of opportunities and obstacles faced by emerging agents.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: Approximately 16 country-specific interviews with rheumatologists and nephrologists.
Epidemiology: Diagnosed prevalence of SLE by country and subpopulations (nonrenal SLE and lupus nephritis).
Population segments in market forecast: Total population, nonrenal SLE population, renal SLE (LN) population.
Emerging therapies: Phase II: 16 drugs; Phase III: 5 drugs.